Danaher Corporation $DHR Shares Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. lifted its holdings in Danaher Corporation (NYSE:DHR) by 150.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 171,200 shares of the conglomerate’s stock after purchasing an additional 102,865 shares during the period. Danaher makes up 3.6% of Nan Fung Trinity HK Ltd.’s holdings, making the stock its 8th biggest holding. Nan Fung Trinity HK Ltd.’s holdings in Danaher were worth $37,929,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Gunderson Capital Management LLC acquired a new position in Danaher during the 3rd quarter worth $765,000. EP Wealth Advisors LLC purchased a new stake in Danaher during the 2nd quarter worth about $3,807,000. Frank Rimerman Advisors LLC raised its position in Danaher by 181.9% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock valued at $9,051,000 after purchasing an additional 26,363 shares in the last quarter. Birch Hill Investment Advisors LLC raised its position in Danaher by 9.6% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock valued at $8,984,000 after purchasing an additional 3,553 shares in the last quarter. Finally, Forbes J M & Co. LLP boosted its stake in shares of Danaher by 141.6% in the 3rd quarter. Forbes J M & Co. LLP now owns 4,276 shares of the conglomerate’s stock valued at $947,000 after buying an additional 2,506 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $232.08 on Friday. The firm has a market capitalization of $163.28 billion, a PE ratio of 37.98, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. The business’s fifty day moving average price is $222.11 and its 200 day moving average price is $201.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.29. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. The company had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. Danaher’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the firm earned $1.89 earnings per share. On average, sell-side analysts anticipate that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a $0.40 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is presently 26.19%.

Insider Transactions at Danaher

In other news, CAO Christopher Bouda sold 7,598 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the sale, the chief accounting officer owned 9,107 shares of the company’s stock, valued at approximately $2,136,137.92. This trade represents a 45.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregory Milosevich sold 2,100 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $230.62, for a total value of $484,302.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $5,158,277.54. The trade was a 8.58% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on DHR. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Monday, October 26th. UBS Group restated a “buy” rating and set a $260.00 target price on shares of Danaher in a research note on Thursday, October 22nd. Royal Bank Of Canada raised their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Robert W. Baird lifted their price target on shares of Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. Finally, Stifel Nicolaus boosted their price target on shares of Danaher from $220.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $242.91.

Danaher Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.